UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): January 30, 2024 (January 24, 2024)
HCA Healthcare, Inc.
(Exact Name of Registrant as Specified in its Charter)
Delaware | 001-11239 | 27-3865930 | ||
(State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(I.R.S. Employer Identification No.) |
One Park Plaza, Nashville, Tennessee |
37203 | |
(Address of Principal Executive Offices) | (Zip Code) |
(615) 344-9551
(Registrant’s Telephone Number, including Area Code)
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each Class |
Trading |
Name of each exchange on which registered |
||
Common Stock, $.01 par value per share | HCA | New York Stock Exchange |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. | Results of Operations and Financial Condition. |
On January 30, 2024, HCA Healthcare, Inc. (the “Company”) issued a press release announcing, among other matters, its results of operations for the fourth quarter and year ended December 31, 2023, the text of which is set forth as Exhibit 99.1.
Item 5.02. | Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
Retirement of William B. Rutherford as Executive Vice President and Chief Financial Officer of the Company
On January 24, 2024, William B. Rutherford notified the Company of his intent to retire from his position as Executive Vice President and Chief Financial Officer, effective May 1, 2024.
A copy of the press release issued by the Company relating to Mr. Rutherford’s retirement is attached hereto as Exhibit 99.1 and incorporated herein by reference.
Appointment of Michael A. Marks as Executive Vice President and Chief Financial Officer of the Company
In conjunction with Mr. Rutherford’s retirement, on January 30, 2024, the Company announced that Michael A. Marks, age 54, will succeed Mr. Rutherford as Executive Vice President and Chief Financial Officer, effective May 1, 2024. Mr. Marks joined HCA Healthcare in 1996 and has served as Senior Vice President — Finance since January 1, 2023. Mr. Marks previously served as Vice President — Financial Operations Support from March 2021 to December 2022. Prior to that time, he served as CFO of the National Group from December 2008 to February 2021 and CFO of the West Florida Division from January 2006 to November 2008.
Beginning on the effective date of Mr. Marks’ appointment, the Compensation Committee (the “Committee”) of the Board of Directors of the Company has approved a base salary of $900,000 for Mr. Marks. In addition, in connection with his appointment, the Committee determined to grant Mr. Marks a long-term equity incentive award with a total target grant date value of $2,000,000 (the “Equity Award”), with fifty percent (50%) of the target award in the form of stock appreciation rights which vest over four years and the other fifty percent (50%) of the target award in the form of performance share units which vest upon achievement of a cumulative three year earnings per share goal, in each case, in accordance with the terms and conditions of the award agreements and the 2020 Stock Incentive Plan for Key Employees of HCA Healthcare, Inc. and its Affiliates. The Equity Award is anticipated to be granted on or about May 1, 2024. Other than with respect to the foregoing, Mr. Marks is not a party to any material plan, contract or arrangement with the Company other than the HCA Supplemental Executive Retirement Plan and other plans and arrangements generally available to all Executive Vice President-level officers of the Company and as disclosed in the Company’s definitive proxy statement on Schedule 14A filed with the U.S. Securities and Exchange Commission on March 10, 2023.
There is no arrangement or understanding between Mr. Marks and any other person pursuant to which Mr. Marks was appointed. There are no family relationships, as defined in Item 401 of Regulation S-K, between Mr. Marks and any of the Company’s executive officers or directors or persons nominated or chosen to become a director or executive officer. There are no transactions in which Mr. Marks has an interest requiring disclosure under Item 404(a) of Regulation S-K.
A copy of the press release issued by the Company relating to Mr. Marks’ appointment as the Company’s Executive Vice President and Chief Financial Officer is attached hereto as Exhibit 99.1 and incorporated herein by reference.
Item 7.01. | Regulation FD Disclosure. |
On January 30, 2024, the Company issued a press release announcing, among other matters, its results of operations for the fourth quarter and year ended December 31, 2023 as well as the matters discussed in Item 5.02, the text of which is set forth as Exhibit 99.1.
Item 8.01. | Other Events. |
On January 30, 2024, the Company announced that its Board of Directors had authorized an additional share repurchase program for up to $6 billion of the Company’s outstanding common stock. Repurchases will be made in accordance with applicable securities laws from time to time in the open market, through privately negotiated transactions, or otherwise.
On January 30, 2024, the Company also announced that its Board of Directors had declared a quarterly cash dividend of $0.66 per share of the Company’s common stock. The dividend will be paid on March 29, 2024 to stockholders of record at the close of business on March 15, 2024.
Item 9.01. | Financial Statements and Exhibits. |
(d) Exhibits:
Exhibit 99.1 | Press Release, dated January 30, 2024. | |
Exhibit 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
HCA HEALTHCARE, INC. |
/s/ John M. Franck II |
John M. Franck II |
Vice President – Legal & Corporate Secretary |
Date: January 30, 2024
Exhibit 99.1
FOR IMMEDIATE RELEASE | ||
INVESTOR CONTACT: | MEDIA CONTACT: |
|
Frank Morgan | Harlow Sumerford |
|
615-344-2688 | 615-344-1851 |
HCA HEALTHCARE REPORTS FOURTH QUARTER 2023 RESULTS
AND PROVIDES 2024 GUIDANCE
BILL RUTHERFORD TO RETIRE AND MIKE MARKS TO BECOME CFO
Nashville, Tenn., January 30, 2024 – HCA Healthcare, Inc. (NYSE: HCA) today announced financial and operating results for the fourth quarter ended December 31, 2023.
Key fourth quarter metrics (all percentage changes compare 4Q 2023 to 4Q 2022 unless otherwise noted):
● | Revenues totaled $17.303 billion |
● | Net income attributable to HCA Healthcare, Inc. totaled $1.607 billion, or $5.93 per diluted share |
● | Adjusted EBITDA totaled $3.618 billion |
● | Cash flows from operating activities totaled $2.674 billion |
● | Same facility admissions increased 3.1 percent while same facility equivalent admissions increased 3.9 percent |
“In the quarter, we experienced strong demand for services across our diversified portfolio of markets, facilities, and service lines. This growth coupled with improved cost trends drove solid financial performance in the fourth quarter. Once again, our people have delivered positive outcomes for our patients, the communities we serve, and our other stakeholders. I want to thank them for their hard work and everything they do for our company,” said Sam Hazen, Chief Executive Officer of HCA Healthcare.
Revenues in the fourth quarter of 2023 totaled $17.303 billion, compared to $15.497 billion in the fourth quarter of 2022. Net income attributable to HCA Healthcare, Inc. totaled $1.607 billion, or $5.93 per diluted share, compared to $2.081 billion, or $7.28 per diluted share, in the fourth quarter of 2022. Results for the fourth quarter of 2023 include gains on sales of facilities of $7 million, or $0.03 per diluted share. Results for the fourth quarter of 2022 include gains on sales of facilities of $1.326 billion, or $2.64 per diluted share, related to sales of our controlling interests in certain healthcare entities.
1
For the fourth quarter of 2023, Adjusted EBITDA totaled $3.618 billion, compared to $3.179 billion in the fourth quarter of 2022. Adjusted EBITDA is a non-GAAP financial measure. A table providing supplemental information on Adjusted EBITDA and reconciling net income attributable to HCA Healthcare, Inc. to Adjusted EBITDA is included in this release.
Same facility admissions increased 3.1 percent while same facility equivalent admissions increased 3.9 percent in the fourth quarter of 2023, compared to the prior year period. Same facility emergency room visits increased 2.1 percent in the fourth quarter of 2023, compared to the prior year period. Same facility inpatient surgeries increased 1.0 percent, and same facility outpatient surgeries increased 0.7 percent in the fourth quarter of 2023, compared to the same period of 2022. Same facility revenue per equivalent admission increased 6.9 percent in the fourth quarter of 2023, compared to the fourth quarter of 2022.
Year Ended December 31, 2023
Revenues for the year ended December 31, 2023 totaled $64.968 billion, compared to $60.233 billion for the year ended December 31, 2022. Net income attributable to HCA Healthcare, Inc. was $5.242 billion, or $18.97 per diluted share, for the year ended December 31, 2023 compared to $5.643 billion, or $19.15 per diluted share, for the year ended December 31, 2022. Results for the year ended December 31, 2023 include losses on sales of facilities of $5 million, or $0.04 per diluted share. Results for the year ended December 31, 2022 include gains on sales of facilities of $1.301 billion, or $2.46 per diluted share, and losses on retirement of debt of $78 million, or $0.20 per diluted share.
For 2023, Adjusted EBITDA totaled $12.726 billion, compared to $12.067 billion in 2022. Adjusted EBITDA is a non-GAAP financial measure. A table providing supplemental information on Adjusted EBITDA and reconciling net income attributable to HCA Healthcare, Inc. to Adjusted EBITDA is included in this release.
Balance Sheet and Cash Flows from Operations
As of December 31, 2023, HCA Healthcare, Inc.’s balance sheet reflected cash and cash equivalents of $935 million, total debt of $39.593 billion, and total assets of $56.211 billion. During the fourth quarter of 2023, capital expenditures totaled $1.159 billion, excluding acquisitions. Cash flows provided by operating activities in the fourth quarter of 2023 totaled $2.674 billion, compared to $2.527 billion in the fourth quarter of 2022.
During the fourth quarter of 2023, the Company repurchased 3.647 million shares of its common stock at a cost of $910 million. The Company had $775 million remaining under its repurchase authorization as of December 31, 2023. As of December 31, 2023, the Company had $6.107 billion of availability under its credit facilities.
Share Repurchase Program
The HCA Healthcare, Inc. Board of Directors has authorized an additional share repurchase program for up to $6 billion of the Company’s outstanding common stock. Repurchases will be made in accordance with applicable securities laws and may be made at management’s discretion from time to time in the open market, through privately negotiated transactions, or otherwise. The repurchase program has no time limit and may be suspended for periods or discontinued at any time.
2
Dividend
HCA today announced that its Board of Directors declared a quarterly cash dividend of $0.66 per share on the Company’s common stock. The dividend will be paid on March 29, 2024 to stockholders of record at the close of business on March 15, 2024.
The declaration and payment of any future dividend will be subject to the discretion of the Board of Directors and will depend on a variety of factors, including the Company’s financial condition, results of operations, and contractual restrictions. Future dividends are expected to be funded by cash balances and future cash flows from operations.
2024 Guidance
Today, the Company issued the following estimated guidance for 2024:
2024 Guidance Range | ||
Revenues |
$67.75 to $70.25 billion |
|
Net Income Attributable to HCA Healthcare, Inc. |
$5.20 to $5.60 billion |
|
Adjusted EBITDA |
$12.85 to $13.55 billion |
|
EPS (diluted) |
$19.70 to $21.20 per diluted share |
Capital expenditures for 2024, excluding acquisitions, are estimated to be in the range of $5.1 to $5.3 billion.
The Company’s 2024 guidance contains a number of assumptions, including, among others, the Company’s current expectations regarding patient volumes and payor mix as well as general economic conditions, including inflation, and excludes the impact of items such as, but not limited to, gains or losses on sales of facilities, losses on retirement of debt, legal claims costs and impairment of long-lived assets.
Adjusted EBITDA is a non-GAAP financial measure. A table reconciling forecasted net income attributable to HCA Healthcare, Inc. to forecasted Adjusted EBITDA is included in this release.
The Company’s guidance is based on current plans and expectations and is subject to a number of known and unknown uncertainties and risks, including those set forth below in the Company’s “Forward-Looking Statements.”
CFO Announcement
HCA Healthcare is also announcing today that Bill Rutherford has decided to retire as Executive Vice President and Chief Financial Officer (“CFO”) after a 34-year career with the company. Mike Marks, HCA Healthcare’s current Senior Vice President, Finance, will succeed Mr. Rutherford as Executive Vice President and CFO, effective May 1, 2024.
“Bill has announced his plan to retire from HCA after 34 years with the company,” said Sam Hazen, Chief Executive Officer of HCA Healthcare. “Bill has had a tremendous impact during his ten years as CFO. The impressive operating results and shareholder returns achieved throughout his tenure are a testament to his leadership and disciplined approach to driving profitable growth. Without question, Bill’s legacy will endure.”
3
“Bill has also developed an incredibly high-performing finance team, including Mike, who is an accomplished finance professional and respected leader. I am thrilled for Mike to take on the CFO role and couldn’t be more confident in his ability to continue to advance our company’s success,” said Hazen. “I want to thank Bill for his many contributions to HCA and congratulate him on his upcoming retirement. I also want to welcome Mike as the new CFO,” said Hazen. “Mike has worked closely with Bill, the senior team, and myself. He will be an exceptional CFO as we continue to deliver on our commitment to the care and improvement of human life while keeping our financial foundation strong.”
Mr. Marks joined HCA Healthcare in 1996 and has held a number of positions in accounting and finance, including Senior Vice President — Finance, Vice President — Financial Operations Support, CFO of the National Group and CFO of the West Florida Division.
Annual Stockholders’ Meeting
The Company’s 2024 annual stockholders’ meeting will be held virtually on April 25, 2024 at 2:00 p.m. Central Time for stockholders of record as of February 26, 2024.
Earnings Conference Call
HCA Healthcare will host a conference call for investors at 9:00 a.m. Central Time today. All interested investors are invited to access a live audio broadcast of the call via webcast. The broadcast also will be available on a replay basis beginning this afternoon. The webcast can be accessed through the Company’s Investor Relations web page at https://investor.hcahealthcare.com/events-and-presentations/default.aspx.
About the Company
As of December 31, 2023, HCA operated 186 hospitals and approximately 2,400 ambulatory sites of care, including surgery centers, freestanding emergency rooms, urgent care centers and physician clinics, in 20 states and the United Kingdom.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the federal securities laws, which involve risks and uncertainties. Forward-looking statements include the Company’s financial guidance for the year ending December 31, 2024, as well as other statements that do not relate solely to historical or current facts. Forward-looking statements can be identified by the use of words like “may,” “believe,” “will,” “expect,” “project,” “estimate,” “anticipate,” “plan,” “initiative” or “continue.” These forward-looking statements are based on our current plans and expectations and are subject to a number of known and unknown uncertainties and risks, many of which are beyond our control, which could significantly affect current plans and expectations and our future financial position and results of operations.
4
These factors include, but are not limited to, (1) changes in or related to general economic conditions nationally and regionally in our markets, including inflation and economic and business conditions (and the impact thereof on the economy, financial markets and banking industry); changes in revenues due to declining patient volumes; changes in payer mix (including increases in uninsured and underinsured patients); potential increased expenses related to labor, supply chain or other expenditures; workforce disruptions; supply shortages and disruptions (including as a result of geopolitical disruptions); and the impact of potential federal government shutdowns, (2) the impact of our significant indebtedness and the ability to refinance such indebtedness on acceptable terms, (3) the impact of current and future federal and state health reform initiatives and possible changes to other federal, state or local laws and regulations affecting the health care industry, including, but not limited to, proposals to expand coverage of federally-funded insurance programs as an alternative to private insurance or establish a single-payer system (such reforms often referred to as “Medicare for All”), (4) the effects related to the implementation of sequestration spending reductions required under the Budget Control Act of 2011, related legislation extending these reductions and those required under the Pay-As-You-Go Act of 2010 as a result of the federal budget deficit impact of the American Rescue Plan Act of 2021, and the potential for future deficit reduction legislation that may alter these spending reductions, which include cuts to Medicare payments, or create additional spending reductions, (5) increases in the amount and risk of collectability of uninsured accounts and deductibles and copayment amounts for insured accounts, (6) the ability to achieve operating and financial targets, attain expected levels of patient volumes and revenues, and control the costs of providing services, (7) possible changes in Medicare, Medicaid and other state programs, including Medicaid supplemental payment programs or Medicaid waiver programs, that may impact reimbursements to health care providers and insurers and the size of the uninsured or underinsured population, (8) personnel-related capacity constraints, increases in wages and the ability to attract, utilize and retain qualified management and other personnel, including affiliated physicians, nurses and medical and technical support personnel, (9) the highly competitive nature of the health care business, (10) changes in service mix, revenue mix and surgical volumes, including potential declines in the population covered under third-party payer agreements, the ability to enter into and renew third-party payer provider agreements on acceptable terms and the impact of consumer-driven health plans and physician utilization trends and practices, (11) the efforts of health insurers, health care providers, large employer groups and others to contain health care costs, (12) the outcome of our continuing efforts to monitor, maintain and comply with appropriate laws, regulations, policies and procedures, (13) the availability and terms of capital to fund the expansion of our business and improvements to our existing facilities, (14) changes in accounting practices, (15) the emergence of and effects related to pandemics, epidemics and outbreaks of infectious diseases or other public health crises, including but not limited to developments related to COVID-19, (16) future divestitures which may result in charges and possible impairments of long-lived assets, (17) changes in business strategy or development plans, (18) delays in receiving payments for services provided, (19) the outcome of pending and any future tax audits, disputes and litigation associated with our tax positions, (20) the impact of known and unknown government investigations, litigation and other claims that may be made against us, (21) the impact of actual and potential cybersecurity incidents or security breaches, including the data security incident disclosed in July 2023, (22) our ongoing ability to demonstrate meaningful use of certified electronic health record technology and the impact of interoperability requirements, (23) the impact of natural disasters, such as hurricanes and floods, physical risks from climate change or similar events beyond our control, (24) changes in U.S. federal, state, or foreign tax laws including interpretive guidance that may be issued by taxing authorities or other standard setting bodies, (25) the results of our efforts to use technology and resilience initiatives to drive efficiencies, better outcomes and an enhanced patient experience, and (26) other risk factors described in our annual report on Form 10-K for the year ended December 31, 2022 and our other filings with the Securities and Exchange Commission. Many of the factors that will determine our future results are beyond our ability to control or predict. In light of the significant uncertainties inherent in the forward-looking statements contained herein, readers should not place undue reliance on forward-looking statements, which reflect management’s views only as of the date hereof. We undertake no obligation to revise or update any forward-looking statements, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise. All references to “Company,” “HCA” and “HCA Healthcare” as used throughout this release refer to HCA Healthcare, Inc. and its affiliates.
5
HCA Healthcare, Inc.
Condensed Consolidated Comprehensive Income Statements
Fourth Quarter
Unaudited
(Dollars in millions, except per share amounts)
2023 | 2022 | |||||||||||||||
|
|
|
|
|||||||||||||
Amount | Ratio | Amount | Ratio | |||||||||||||
Revenues |
$17,303 | 100.0 | % | $15,497 | 100.0 | % | ||||||||||
Salaries and benefits |
7,570 | 43.7 | 7,055 | 45.5 | ||||||||||||
Supplies |
2,584 | 14.9 | 2,429 | 15.7 | ||||||||||||
Other operating expenses |
3,559 | 20.7 | 2,850 | 18.4 | ||||||||||||
Equity in earnings of affiliates |
(28) | (0.2) | (16) | (0.1) | ||||||||||||
Depreciation and amortization |
789 | 4.5 | 750 | 4.9 | ||||||||||||
Interest expense |
491 | 2.8 | 453 | 2.9 | ||||||||||||
Gains on sales of facilities |
(7) | - | (1,326) | (8.6) | ||||||||||||
|
|
|
|
|||||||||||||
14,958 | 86.4 | 12,195 | 78.7 | |||||||||||||
|
|
|
|
|||||||||||||
Income before income taxes |
2,345 | 13.6 | 3,302 | 21.3 | ||||||||||||
Provision for income taxes |
484 | 2.8 | 656 | 4.2 | ||||||||||||
|
|
|
|
|||||||||||||
Net income |
1,861 | 10.8 | 2,646 | 17.1 | ||||||||||||
Net income attributable to noncontrolling interests |
254 | 1.5 | 565 | 3.7 | ||||||||||||
|
|
|
|
|||||||||||||
Net income attributable to HCA Healthcare, Inc. |
$1,607 | 9.3 | $2,081 | 13.4 | ||||||||||||
|
|
|
|
|||||||||||||
Diluted earnings per share |
$5.93 | $7.28 | ||||||||||||||
Shares used in computing diluted earnings per share (millions) |
271.186 | 285.663 | ||||||||||||||
Comprehensive income attributable to HCA Healthcare, Inc. |
$1,673 | $2,183 | ||||||||||||||
|
|
|
|
6
HCA Healthcare, Inc.
Condensed Consolidated Comprehensive Income Statements
For the Years Ended December 31, 2023 and 2022
Unaudited
(Dollars in millions, except per share amounts)
2023 | 2022 | |||||||||||||||
|
|
|
|
|||||||||||||
Amount | Ratio | Amount | Ratio | |||||||||||||
Revenues |
$64,968 | 100.0 | % | $60,233 | 100.0 | % | ||||||||||
Salaries and benefits |
29,487 | 45.4 | 27,685 | 46.0 | ||||||||||||
Supplies |
9,902 | 15.2 | 9,371 | 15.6 | ||||||||||||
Other operating expenses |
12,875 | 19.8 | 11,155 | 18.5 | ||||||||||||
Equity in earnings of affiliates |
(22) | - | (45) | (0.1) | ||||||||||||
Depreciation and amortization |
3,077 | 4.7 | 2,969 | 5.0 | ||||||||||||
Interest expense |
1,938 | 3.0 | 1,741 | 2.9 | ||||||||||||
Losses (gains) on sales of facilities |
5 | - | (1,301) | (2.2) | ||||||||||||
Losses on retirement of debt |
- | - | 78 | 0.1 | ||||||||||||
|
|
|
|
|||||||||||||
57,262 | 88.1 | 51,653 | 85.8 | |||||||||||||
|
|
|
|
|||||||||||||
Income before income taxes |
7,706 | 11.9 | 8,580 | 14.2 | ||||||||||||
Provision for income taxes |
1,615 | 2.5 | 1,746 | 2.9 | ||||||||||||
|
|
|
|
|||||||||||||
Net income |
6,091 | 9.4 | 6,834 | 11.3 | ||||||||||||
Net income attributable to noncontrolling interests |
849 | 1.3 | 1,191 | 1.9 | ||||||||||||
|
|
|
|
|||||||||||||
Net income attributable to HCA Healthcare, Inc. |
$5,242 | 8.1 | $5,643 | 9.4 | ||||||||||||
|
|
|
|
|||||||||||||
Diluted earnings per share |
$18.97 | $19.15 | ||||||||||||||
Shares used in computing diluted earnings per share (millions) |
276.412 | 294.666 | ||||||||||||||
Comprehensive income attributable to HCA Healthcare, Inc. |
$5,307 | $5,557 | ||||||||||||||
|
|
|
|
7
HCA Healthcare, Inc.
Condensed Consolidated Balance Sheets
Unaudited
(Dollars in millions)
December 31, | September 30, | December 31, | ||||||||||
2023 | 2023 | 2022 | ||||||||||
ASSETS |
||||||||||||
Current assets: |
||||||||||||
Cash and cash equivalents |
$935 | $891 | $908 | |||||||||
Accounts receivable |
9,958 | 9,182 | 8,891 | |||||||||
Inventories |
2,021 | 2,030 | 2,068 | |||||||||
Other |
2,013 | 2,191 | 1,776 | |||||||||
|
|
|
|
|
|
|
|
|
||||
14,927 | 14,294 | 13,643 | ||||||||||
Property and equipment, at cost |
58,548 | 57,772 | 54,757 | |||||||||
Accumulated depreciation |
(30,833 | ) | (30,655 | ) | (29,182 | ) | ||||||
|
|
|
|
|
|
|
|
|
||||
27,715 | 27,117 | 25,575 | ||||||||||
Investments of insurance subsidiaries |
477 | 382 | 381 | |||||||||
Investments in and advances to affiliates |
756 | 739 | 823 | |||||||||
Goodwill and other intangible assets |
9,945 | 9,778 | 9,653 | |||||||||
Right-of-use operating lease assets |
2,207 | 2,079 | 2,065 | |||||||||
Other |
184 | 200 | 298 | |||||||||
|
|
|
|
|
|
|
|
|
||||
$56,211 | $54,589 | $52,438 | ||||||||||
|
|
|
|
|
|
|
|
|
||||
LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT) |
||||||||||||
Current liabilities: |
||||||||||||
Accounts payable |
$4,233 | $4,139 | $4,239 | |||||||||
Accrued salaries |
2,127 | 1,912 | 1,712 | |||||||||
Other accrued expenses |
3,871 | 3,803 | 3,581 | |||||||||
Long-term debt due within one year |
2,424 | 2,553 | 370 | |||||||||
|
|
|
|
|
|
|
|
|
||||
12,655 | 12,407 | 9,902 | ||||||||||
Long-term debt, less debt issuance costs and discounts of $333, $341 and $301 |
37,169 | 36,793 | 37,714 | |||||||||
Professional liability risks |
1,557 | 1,590 | 1,528 | |||||||||
Right-of-use operating lease obligations |
1,903 | 1,776 | 1,752 | |||||||||
Income taxes and other liabilities |
1,867 | 1,666 | 1,615 | |||||||||
Stockholders’ equity (deficit): |
||||||||||||
Stockholders’ deficit attributable to HCA Healthcare, Inc. |
(1,774 | ) | (2,477 | ) | (2,767 | ) | ||||||
Noncontrolling interests |
2,834 | 2,834 | 2,694 | |||||||||
|
|
|
|
|
|
|
|
|
||||
1,060 | 357 | (73 | ) | |||||||||
|
|
|
|
|
|
|
|
|
||||
$56,211 | $54,589 | $52,438 | ||||||||||
|
|
|
|
|
|
|
|
|
8
HCA Healthcare, Inc.
Condensed Consolidated Statements of Cash Flows
For the Years Ended December 31, 2023 and 2022
Unaudited
(Dollars in millions)
2023 | 2022 | |||||||
Cash flows from operating activities: |
||||||||
Net income |
$6,091 | $6,834 | ||||||
Adjustments to reconcile net income to net cash provided by operating activities: |
||||||||
Increase (decrease) in cash from operating assets and liabilities: |
||||||||
Accounts receivable |
(935 | ) | (797 | ) | ||||
Inventories and other assets |
(126 | ) | (59 | ) | ||||
Accounts payable and accrued expenses |
604 | (296 | ) | |||||
Depreciation and amortization |
3,077 | 2,969 | ||||||
Income taxes |
229 | 571 | ||||||
Losses (gains) on sales of facilities |
5 | (1,301 | ) | |||||
Losses on retirement of debt |
- | 78 | ||||||
Amortization of debt issuance costs and discounts |
35 | 29 | ||||||
Share-based compensation |
262 | 341 | ||||||
Other |
189 | 153 | ||||||
|
|
|
|
|
|
|||
Net cash provided by operating activities |
9,431 | 8,522 | ||||||
|
|
|
|
|
|
|||
Cash flows from investing activities: |
||||||||
Purchase of property and equipment |
(4,744 | ) | (4,395 | ) | ||||
Acquisition of hospitals and health care entities |
(635 | ) | (224 | ) | ||||
Sales of hospitals and health care entities |
193 | 1,237 | ||||||
Change in investments |
(112 | ) | 14 | |||||
Other |
(19 | ) | (21 | ) | ||||
|
|
|
|
|
|
|||
Net cash used in investing activities |
(5,317 | ) | (3,389 | ) | ||||
|
|
|
|
|
|
|||
Cash flows from financing activities: |
||||||||
Issuances of long-term debt |
3,224 | 5,997 | ||||||
Net change in revolving credit facilities |
(1,020 | ) | 120 | |||||
Repayment of long-term debt |
(909 | ) | (2,830 | ) | ||||
Distributions to noncontrolling interests |
(640 | ) | (1,025 | ) | ||||
Payment of debt issuance costs |
(31 | ) | (53 | ) | ||||
Payment of dividends |
(661 | ) | (653 | ) | ||||
Repurchase of common stock |
(3,811 | ) | (7,000 | ) | ||||
Other |
(246 | ) | (212 | ) | ||||
|
|
|
|
|
|
|||
Net cash used in financing activities |
(4,094 | ) | (5,656 | ) | ||||
|
|
|
|
|
|
|||
Effect of exchange rate changes on cash and cash equivalents |
7 | (20 | ) | |||||
|
|
|
|
|
|
|||
Change in cash and cash equivalents |
27 | (543 | ) | |||||
Cash and cash equivalents at beginning of period |
908 | 1,451 | ||||||
|
|
|
|
|
|
|||
Cash and cash equivalents at end of period |
$935 | $908 | ||||||
|
|
|
|
|
|
|||
Interest payments |
$1,892 | $1,662 | ||||||
Income tax payments, net |
$1,386 | $1,175 |
9
HCA Healthcare, Inc.
Operating Statistics
Fourth Quarter | For the Years Ended December 31, |
|||||||||||||||
2023 |
2022 |
2023 |
2022 |
|||||||||||||
Operations: |
||||||||||||||||
Number of Hospitals |
186 | 182 | 186 | 182 | ||||||||||||
Number of Freestanding Outpatient Surgery Centers* |
124 | 126 | 124 | 126 | ||||||||||||
Licensed Beds at End of Period |
49,588 | 49,281 | 49,588 | 49,281 | ||||||||||||
Weighted Average Beds in Service |
42,072 | 42,119 | 41,873 | 41,982 | ||||||||||||
Reported: |
||||||||||||||||
Admissions |
544,554 | 530,298 | 2,130,728 | 2,075,459 | ||||||||||||
% Change |
2.7 | % | 2.7 | % | ||||||||||||
Equivalent Admissions |
974,561 | 931,990 | 3,788,434 | 3,611,299 | ||||||||||||
% Change |
4.6 | % | 4.9 | % | ||||||||||||
Revenue per Equivalent Admission |
$ | 17,755 | $ | 16,628 | $ | 17,149 | $ | 16,679 | ||||||||
% Change |
6.8 | % | 2.8 | % | ||||||||||||
Inpatient Revenue per Admission |
$ | 18,992 | $ | 17,634 | $ | 18,201 | $ | 17,361 | ||||||||
% Change |
7.7 | % | 4.8 | % | ||||||||||||
Patient Days |
2,674,331 | 2,648,683 | 10,483,236 | 10,504,145 | ||||||||||||
% Change |
1.0 | % | -0.2 | % | ||||||||||||
Equivalent Patient Days |
4,786,197 | 4,655,841 | 18,639,194 | 18,277,212 | ||||||||||||
% Change |
2.8 | % | 2.0 | % | ||||||||||||
Inpatient Surgery Cases |
132,417 | 131,840 | 528,845 | 522,151 | ||||||||||||
% Change |
0.4 | % | 1.3 | % | ||||||||||||
Outpatient Surgery Cases |
270,286 | 265,610 | 1,044,415 | 1,023,239 | ||||||||||||
% Change |
1.8 | % | 2.1 | % | ||||||||||||
Emergency Room Visits |
2,452,395 | 2,412,781 | 9,342,783 | 8,971,951 | ||||||||||||
% Change |
1.6 | % | 4.1 | % | ||||||||||||
Outpatient Revenues as a |
||||||||||||||||
Percentage of Patient Revenues |
38.4 | % | 37.5 | % | 38.3 | % | 37.6 | % | ||||||||
Average Length of Stay (days) |
4.911 | 4.995 | 4.920 | 5.061 | ||||||||||||
Occupancy** |
72.5 | % | 72.0 | % | 72.3 | % | 72.1 | % | ||||||||
Same Facility: |
||||||||||||||||
Admissions |
542,628 | 526,259 | 2,127,112 | 2,059,561 | ||||||||||||
% Change |
3.1 | % | 3.3 | % | ||||||||||||
Equivalent Admissions |
959,366 | 923,585 | 3,750,098 | 3,577,457 | ||||||||||||
% Change |
3.9 | % | 4.8 | % | ||||||||||||
Revenue per Equivalent Admission |
$ | 17,672 | $ | 16,533 | $ | 17,080 | $ | 16,637 | ||||||||
% Change |
6.9 | % | 2.7 | % | ||||||||||||
Inpatient Revenue per Admission |
$ | 19,025 | $ | 17,530 | $ | 18,210 | $ | 17,313 | ||||||||
% Change |
8.5 | % | 5.2 | % | ||||||||||||
Inpatient Surgery Cases |
132,056 | 130,804 | 528,085 | 517,898 | ||||||||||||
% Change |
1.0 | % | 2.0 | % | ||||||||||||
Outpatient Surgery Cases |
263,398 | 261,685 | 1,026,639 | 1,002,076 | ||||||||||||
% Change |
0.7 | % | 2.5 | % | ||||||||||||
Emergency Room Visits |
2,445,405 | 2,395,650 | 9,328,741 | 8,907,055 | ||||||||||||
% Change |
2.1 | % | 4.7 | % |
* | Excludes freestanding endoscopy centers (24 centers at December 31, 2023 and 21 centers at December 31, 2022). |
** | Reflects the rate of occupancy (patient days and observations) based on weighted average beds in service. |
10
HCA Healthcare, Inc.
Supplemental Non-GAAP Disclosures
Operating Results Summary
(Dollars in millions, except per share amounts)
For the Years | ||||||||||||||||
Fourth Quarter | Ended December 31, | |||||||||||||||
2023 | 2022 | 2023 | 2022 | |||||||||||||
Revenues | $17,303 | $15,497 | $64,968 | $60,233 | ||||||||||||
Net income attributable to HCA Healthcare, Inc. |
$1,607 | $2,081 | $5,242 | $5,643 | ||||||||||||
Losses (gains) on sales of facilities (net of tax) |
(9 | ) | (755 | ) | 12 | (727 | ) | |||||||||
Losses on retirement of debt (net of tax) |
- | - | - | 60 | ||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|||||
Net income attributable to HCA Healthcare, Inc., excluding losses (gains) on sales of facilities |
1,598 | 1,326 | 5,254 | 4,976 | ||||||||||||
Depreciation and amortization |
789 | 750 | 3,077 | 2,969 | ||||||||||||
Interest expense |
491 | 453 | 1,938 | 1,741 | ||||||||||||
Provision for income taxes |
486 | 422 | 1,608 | 1,527 | ||||||||||||
Net income attributable to noncontrolling interests (b) |
254 | 228 | 849 | 854 | ||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|||||
Adjusted EBITDA (a) |
$3,618 | $3,179 | $12,726 | $12,067 | ||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|||||
Adjusted EBITDA margin (a) |
20.9% | 20.5% | 19.6% | 20.0% | ||||||||||||
Diluted earnings per share: | ||||||||||||||||
Net income attributable to HCA Healthcare, Inc. |
$5.93 | $7.28 | $18.97 | $19.15 | ||||||||||||
Losses (gains) on sales of facilities |
(0.03 | ) | (2.64 | ) | 0.04 | (2.46 | ) | |||||||||
Losses on retirement of debt |
- | - | - | 0.20 | ||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|||||
Net income attributable to HCA Healthcare, Inc., excluding losses (gains) on sales of facilities |
$5.90 | $4.64 | $19.01 | $16.89 | ||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|||||
Shares used in computing diluted earnings per share (millions) |
271.186 | 285.663 | 276.412 | 294.666 |
(a) | Net income attributable to HCA Healthcare, Inc., excluding losses (gains) on sales of facilities and losses on retirement of debt, and Adjusted EBITDA should not be considered as measures of financial performance under generally accepted accounting principles (“GAAP”). We believe net income attributable to HCA Healthcare, Inc., excluding losses (gains) on sales of facilities and losses on retirement of debt, and Adjusted EBITDA are important measures that supplement discussions and analysis of our results of operations. We believe it is useful to investors to provide disclosures of our results of operations on the same basis used by management. Management relies upon net income attributable to HCA Healthcare, Inc., excluding losses (gains) on sales of facilities and losses on retirement of debt, and Adjusted EBITDA as the primary measures to review and assess operating performance of its health care facilities and their management teams. |
Management and investors review both the overall performance (including net income attributable to HCA Healthcare, Inc., excluding losses (gains) on sales of facilities and losses on retirement of debt, and GAAP net income attributable to HCA Healthcare, Inc.) and operating performance (Adjusted EBITDA) of our health care facilities. Adjusted EBITDA and the Adjusted EBITDA margin (Adjusted EBITDA divided by revenues) are utilized by management and investors to compare our current operating results with the corresponding periods during the previous year and to compare our operating results with other companies in the health care industry. It is reasonable to expect that losses (gains) on sales of facilities and losses on retirement of debt will occur in future periods, but the amounts recognized can vary significantly from period to period, do not directly relate to the ongoing operations of our health care facilities and complicate period comparisons of our results of operations and operations comparisons with other health care companies.
Net income attributable to HCA Healthcare, Inc., excluding losses (gains) on sales of facilities and losses on retirement of debt, and Adjusted EBITDA are not measures of financial performance under GAAP, and should not be considered as alternatives to net income attributable to HCA Healthcare, Inc. as a measure of operating performance or cash flows from operating, investing and financing activities as a measure of liquidity. Because net income attributable to HCA Healthcare, Inc., excluding losses (gains) on sales of facilities and losses on retirement of debt, and Adjusted EBITDA are not measurements determined in accordance with GAAP and are susceptible to varying calculations, net income attributable to HCA Healthcare, Inc., excluding losses (gains) on sales of facilities and losses on retirement of debt, and Adjusted EBITDA, as presented, may not be comparable to other similarly titled measures presented by other companies.
(b) | The 2022 amounts are net of noncontrolling interests related to gains on sales of facilities. |
11
HCA Healthcare, Inc.
Supplemental Non-GAAP Disclosures
2024 Operating Results Forecast
(Dollars in millions, except per share amounts)
For the Year Ending | ||||||||
December 31, 2024 | ||||||||
Low |
High |
|||||||
Revenues |
$67,750 | $70,250 | ||||||
Net income attributable to HCA Healthcare, Inc. (a) |
$5,200 | $5,600 | ||||||
Depreciation and amortization |
3,200 | 3,270 | ||||||
Interest expense |
1,985 | 2,040 | ||||||
Provision for income taxes |
1,615 | 1,740 | ||||||
Net income attributable to noncontrolling interests |
850 | 900 | ||||||
|
|
|
|
|
|
|||
Adjusted EBITDA (a) (b) |
$12,850 | $13,550 | ||||||
|
|
|
|
|
|
|||
Diluted earnings per share: |
||||||||
Net income attributable to HCA Healthcare, Inc. |
$19.70 | $21.20 | ||||||
Shares used in computing diluted earnings per share (millions) |
264.000 | 264.000 |
The Company’s forecasted guidance range is based on current plans and expectations and is subject to a number of known and unknown uncertainties and risks.
(a) | The Company does not forecast the impact of items such as, but not limited to, losses (gains) on sales of facilities, losses on retirement of debt, legal claim costs (benefits) and impairments of long-lived assets because the Company does not believe that it can forecast these items with sufficient accuracy. |
(b) | Adjusted EBITDA should not be considered a measure of financial performance under generally accepted accounting principles (“GAAP”). We believe Adjusted EBITDA is an important measure that supplements discussions and analysis of our results of operations. We believe it is useful to investors to provide disclosures of our results of operations on the same basis used by management. Management relies upon Adjusted EBITDA as a primary measure to review and assess operating performance of its health care facilities and their management teams. |
Management and investors review both the overall performance (including net income attributable to HCA Healthcare, Inc.) and operating performance (Adjusted EBITDA) of our health care facilities. Adjusted EBITDA is utilized by management and investors to compare our current operating results with the corresponding periods during the previous year and to compare our operating results with other companies in the health care industry.
Adjusted EBITDA is not a measure of financial performance under GAAP and should not be considered as an alternative to net income attributable to HCA Healthcare, Inc. as a measure of operating performance or cash flows from operating, investing and financing activities as a measure of liquidity. Because Adjusted EBITDA is not a measurement determined in accordance with GAAP and is susceptible to varying calculations, Adjusted EBITDA, as presented, may not be comparable to other similarly titled measures presented by other companies.
12